Qualitau in the First Quarter: Backlog Starts Turning Into Cash, New Capital Weighs on Profit
Qualitau opened 2026 with 14.8% revenue growth and $9.1 million of operating cash flow, closing part of the question left from 2025. But the 48% drop in net profit came from the cost of new capital, FX effects and option grants, so the next quarters need to prove that the new cash creates per-share growth rather than only a larger balance sheet.
The first quarter at Qualitau gives a positive answer to one of the questions left open at the end of 2025: part of the backlog and shipments did turn into cash. Revenue rose 14.8%, gross margin stayed around 70%, and operating cash flow reached $9.1 million, well above net profit of $2.9 million. This is not a quarter that points to a clear weakening in demand or product pricing. The problem sits in a different layer: net profit was almost cut in half because of finance expenses tied to shekel deposits from the capital raise, share-based payment expense and quarterly recognition of bonus accruals. The current read is therefore better on backlog quality and collection, but less clean on per-share economics after the raise. Q2 and Q3 need to show that deliveries continue turning into revenue and cash, and that the NIS 225 million raised starts working for growth rather than only enlarging the balance sheet.
Backlog Starts Moving Into Collection
Qualitau develops, manufactures and markets testing systems for the semiconductor industry. Its economics depend on backlog, delivery capacity, high gross margins and customer collection, not on financial leverage or asset revaluation. A strong quarter therefore has to prove not only that orders exist, but that they are moving into shipments and cash.
The prior annual analysis left that exact question open. The first quarter gives an initial positive answer. Customer receivables fell from $16.8 million at the end of 2025 to $12.9 million at the end of March 2026, and operating cash flow reached $9.1 million compared with only $0.9 million in the comparable quarter. Inventory also did not swell to support growth, edging down to $16.3 million. At least in this quarter, revenue was not purchased through another stretch in working capital.
The profit-to-cash gap came mainly from working capital release: a $3.9 million decline in customer receivables, a $1.1 million decline in other receivables, a small decrease in inventory and a roughly $0.9 million increase in suppliers. Payables and accruals moved the other way, decreasing by $1.4 million. This was not only liquidity that arrived through the capital raise, but collection from the operating business itself.
Profit Fell in the Capital Layer, Not in Gross Margin
The operating numbers are stronger than the net profit line suggests. Revenue was $16.0 million compared with $14.0 million in the first quarter of 2025, and gross profit rose to $11.3 million. Gross margin was about 70.4%, almost identical to 70.5% in the comparable quarter. For a semiconductor testing-equipment company, holding that margin while growing means the increase did not come through an obvious gross-price concession.
But below gross profit, the hit was sharp. Operating profit fell to $5.3 million from $6.4 million, and net profit fell to $2.9 million from $5.7 million. General and administrative expenses rose mainly because of $1.5 million of share-based payment expense and quarterly recognition of bonus accruals, after the company changed how it recognizes the annual bonus provision. That change added $731,000 of expense in the quarter.
Finance expenses jumped to $2.1 million, mainly because of exchange-rate differences on shekel deposits created after the private placement. This is a real hit to the bottom line, but it does not by itself point to weakening product demand. The more accurate read is a business that is still working, alongside a new capital layer that creates cost, volatility and dilution already visible in per-share profit.
China Exposure Improved, The Far East Is Still Central
In the comparable quarter of 2025, China alone represented 79% of sales. In the first quarter of 2026, China fell to 28%, Taiwan represented 19%, Singapore 16%, and the United States 13%. By region, the Far East was still dominant with $12.2 million of revenue, about 75.8% of the total, but dependence on one country looks much lower.
That diversification matters, but it does not close the risk. Backlog stood at $47.5 million at the end of March and had already risen to $62.7 million near the publication of the financial statements. After the balance-sheet date, the company received three additional orders: $4.2 million from a U.S. customer, $2.28 million from a customer in Asia, and $3.9 million from a customer in Asia, with deliveries expected in Q4 2026 and Q1 2027. Demand is still coming from both the United States and Asia, but Asia remains central.
The company also states that customer orders received from companies registered in China for 2026 and 2027 are currently expected to be supplied as planned, and that none of those customers is on the U.S. government restricted list. That is a useful reassurance against a regulatory concern, not a cancellation of the risk. Tariffs, shipping costs, U.S.-China relations and the China-Taiwan environment can still affect delivery timing and costs. The company currently expects no material effect on 2026 gross margin, and that needs to be tested against actual margins later this year.
Conclusion
The private placement changes Qualitau's yardstick. Equity rose to $138.5 million from $65.8 million at the end of 2025, and cash and cash equivalents reached $112.8 million. That is meaningful flexibility, but it already comes with a cost: FX differences on the raised funds, share-based payment expense, dilution, a dividend of about $4.2 million paid in April and a buyback program increased to about NIS 14.2 million. After the balance-sheet date, the company also approved a grant of 55,500 additional options, with total fair value of about $6.7 million and expected expense of about $2.6 million during the rest of 2026.
The first quarter is therefore stronger operationally and weaker accounting-wise than the headline net profit decline suggests. The business did not break: revenue rose, gross margin held, backlog increased after the balance-sheet date, and customers released cash. Relative to the question left from 2025, this is real progress. The company showed at least one quarter in which backlog did not merely sit in the filings, but moved into collection.
The rest of the year will be decided by four numbers: whether receivables continue falling or remain healthy, whether gross margin stays around 70%, how quickly the $62.7 million backlog converts into revenue, and whether China’s lower first-quarter share reflects real diversification or only shipment timing. The market may first see the weak net profit. The analytical value in the report is that cash improved. Now the company needs to make the two lines meet: strong operations, good use of new capital, and per-share profitability that does not erode behind a more liquid balance sheet.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.